London, United Kingdom, January 26, 2026 — GSK announced that the European Commission (EC) has approved an expanded indication for its adjuvanted recombinant Respiratory Syncytial Virus (RSV) vaccine, Arexvy, allowing its use in all adults aged 18 years and older across the European Union and European Economic Area. Previously authorized for adults aged 60 years and older, and for high-risk individuals aged 50–59 years, the expanded approval enables broader protection against RSV-related lower respiratory tract disease. The decision reflects growing recognition of RSV as a significant cause of hospitalization, severe respiratory illness, and mortality among adults, particularly those with chronic health conditions or immune vulnerability.
Science Significance
Arexvy is built on recombinant RSV glycoprotein F stabilized in its prefusion conformation (RSVPreF3), an antigenic structure that enhances immune recognition and neutralizing antibody response. The vaccine is formulated with GSK’s proprietary AS01E adjuvant system, which boosts immune activation and strengthens both humoral and cellular immune responses. This scientific design enables robust and durable protection against RSV lower respiratory tract disease in adults. RSV infection can worsen chronic respiratory and cardiovascular conditions such as chronic obstructive pulmonary disease (COPD), asthma, and heart failure, increasing the risk of pneumonia, hospitalization, and death. Expanding access to an immunologically optimized RSV vaccine represents a meaningful scientific advancement in adult infectious disease prevention.
Regulatory Significance
The European Commission’s expanded approval signals a regulatory milestone in adult RSV immunization, broadening the protective scope of a previously age-limited vaccine. Regulatory authorities evaluated clinical evidence demonstrating vaccine efficacy, safety, and immunogenicity in broader adult populations before granting the expanded label. The decision enables national immunization programs across Europe to determine how best to integrate RSV vaccination for younger adults, particularly those at risk due to underlying medical conditions. GSK also continues to pursue expanded regulatory indications in other global markets, including the United States and Japan, reinforcing its strategy to broaden worldwide adult RSV prevention coverage.
Advertisement
Business Significance
From a commercial standpoint, the expanded adult indication significantly increases the addressable market for Arexvy across Europe. Adult immunization represents a high-growth segment within global vaccine markets, particularly as aging populations expand and respiratory-virus awareness increases. By broadening eligibility to adults aged 18 and older, GSK strengthens Arexvy’s long-term revenue potential and competitive positioning within the RSV vaccine landscape. The expanded approval also supports GSK’s broader vaccines portfolio strategy, reinforcing its leadership in infectious disease prevention and driving sustained investment in next-generation vaccine innovation.
Patients’ Significance
For adult patients, especially those with chronic illnesses, immune compromise, or elevated respiratory risk, expanded access to RSV vaccination provides an opportunity to reduce severe illness, hospitalization, and long-term respiratory complications. RSV can lead to serious health outcomes in adults, including pneumonia, respiratory failure, and worsening of preexisting conditions. Vaccination may help prevent severe disease, reduce strain on healthcare systems, and improve overall quality of life. Younger adults with medical risk factors may particularly benefit from earlier immunization access under the expanded approval framework.
Policy Significance
The expanded RSV vaccine authorization aligns with European public-health policy goals aimed at strengthening adult immunization, preventing respiratory disease outbreaks, and reducing hospitalization burden. RSV remains a major contributor to seasonal respiratory illness, and improved vaccine coverage supports broader strategies to reduce healthcare costs, protect vulnerable populations, and enhance pandemic preparedness. Policymakers may leverage the expanded approval to develop targeted vaccination programs that prioritize high-risk adults and strengthen respiratory-disease prevention infrastructure across the region.
The European Commission approval to expand Arexvy’s use to all adults aged 18 years and older marks a significant advancement in RSV prevention policy and adult immunization strategy. By extending protection beyond older and high-risk groups, GSK is positioned to play a larger role in mitigating the growing RSV burden among adults. As countries consider implementation strategies for broader RSV vaccination, Arexvy stands as a scientifically advanced and policy-relevant tool supporting the prevention of serious respiratory disease across Europe.
Source: GSK press release
